Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)Blue Cross Blue Shield TN HPV tumor status Coverag…
    Ask Trek AI about this page
    Currentblue cross blue shield - tennesseePolicy N/A

    Oral Cancer Screening and Testing

    Customize your policy alerts

    Sign up for all blue cross blue shield - tennessee policy alerts

    Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage criteria and limitations for tests related to oral and oropharyngeal cancer screening and diagnostic testing, including HPV tumor status testing and exclusion of various salivary/genetic biomarker tests and panels. Also lists applicable procedure codes and references to guidelines and regulatory considerations.

    Policy Summary
    Payerblue cross blue shield - tennessee
    PolicyOral Cancer Screening and Testing
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionProvider must document that the individual has oropharyngeal squamous cell carcinoma when requesting HPV tumor status testing (p16 IHC or HPV E6/E7 mRNA).
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes identified in this brief.

    1Covered Indication (HPV tumor status for oropharyngeal SCC)
    4Not Covered Test Categories
    7Key referenced CPT/HCPCS codes listed

    Coverage Summary

    This policy addresses testing related to oral and oropharyngeal cancer with a focus on establishing HPV tumor status for individuals with oropharyngeal squamous cell carcinoma. Coverage is mixed: testing for high-risk HPV tumor status by either HPV E6/E7 mRNA expression or p16 immunohistochemistry (IHC) meets coverage criteria, while multiple salivary- or genomic-based adjunctive assays and certain panels do not meet coverage due to insufficient evidence. Guideline concordance is noted: NCCN, CAP, and ASCO accept p16 IHC as a surrogate for HPV status and recognize HPV E6/E7 mRNA as the gold standard; USPSTF guidance states there is insufficient evidence to recommend screening for oral cancer in asymptomatic adults and does not recommend screening for oral HPV infection.

    Policy statistics
    Covered Indication (HPV tumor status for oropharyngeal SCC)1
    Not Covered Test Categories4
    Key referenced CPT/HCPCS codes listed7

    Medical-Necessity Criteria

    Medically Necessary / Meets Coverage Criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Purpose: To establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma
    • Test modality: testing for high-risk HPV with either mRNA expression testing for HPV E6/E7 OR immunohistochemistry for p16 expression

      Either mRNA E6/E7 or p16 IHC satisfies coverage

    Not Covered / Does Not Meet Coverage Criteria

    The following testing DOES NOT MEET COVERAGE CRITERIA due to lack of sufficient published evidence:

    Any of the following

    • Salivary biomarker testing (e.g., peptides/proteins, nucleic acids, metabolites)
    • Genotyping of HPV (e.g., OraRisk® HPV)
    • Gene expression profiling
    • Panels that incorporate genetic risk factors with nongenetic biomarkers (e.g., mRNA CancerDetect™)

    Coding

    Covered / referenced procedure codes for HPV and related testingmixedCovered
    87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types
    87625Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
    0429UHuman papillomavirus (HPV), oropharyngeal swab, 14 high-risk types; proprietary Omnipathology Oropharyngeal HPV PCR Test
    88342Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure
    88341Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure
    Procedure codes referenced (unlisted/assay)mixed
    81599Unlisted multianalyte assay with algorithmic analysis
    82397Chemiluminescent assay

    Provider Actions

    Documentation Required

    Document indication of oropharyngeal squamous cell carcinoma

    Provider must document that the individual has oropharyngeal squamous cell carcinoma when requesting HPV tumor status testing (p16 IHC or HPV E6/E7 mRNA).

    • 88342
    • 88341
    • 87624
    • 87625
    • 0429U
    Billing Rule

    Use appropriate CPT/HCPCS for HPV and IHC testing

    Report the applicable CPT/HCPCS codes for HPV nucleic acid testing, p16 IHC stains, or unlisted multianalyte assays as referenced in the policy when submitting claims.

    Background & Evidence

    Oral and oropharyngeal cancers are common and carry substantial mortality; estimates cited include roughly ~58,450 diagnoses and ~12,230 deaths in 2024 in the U.S., with squamous cell carcinoma as the predominant histology. Human papillomavirus (HPV) is an important contributor to oropharyngeal cancer, but there is no approved screening test for oral or oropharyngeal HPV infection. Numerous adjunctive, noninvasive tests have been evaluated—salivary biomarkers (mRNA, miRNA, proteins, metabolites), brush cytology, vital staining, autofluorescence and other light-based detection systems, and chemiluminescence devices—but evidence is variable. Systematic reviews and meta-analyses report wide ranges of sensitivity and specificity across modalities, promising results for salivary mRNA/miRNA in some studies, and mixed or limited performance for devices like VELscope and ViziLite. Overall, lack of standardization, interobserver variability, and insufficient high-quality prospective validation limit the clinical adoption of many adjunctive tests.

    SourceKey point
    NCCN / CAP / ASCO concordancep16 immunohistochemistry (IHC) is an accepted surrogate for HPV tumor status and has very good agreement with the gold standard HPV E6/E7 mRNA; mRNA E6/E7 is considered the gold standard for HPV tumor status determination
    USPSTF 2013USPSTF concluded evidence is insufficient to assess benefits and harms of screening for oral cancer in asymptomatic adults and noted organizations do not recommend screening for oral HPV infection
    Systematic reviews / meta-analyses (salivary biomarkers, adjunctive devices, cytology)Systematic reviews/meta-analyses report variable diagnostic accuracy across modalities: salivary mRNA/miRNA show high sensitivity/specificity in some analyses (eg, ~91% sensitivity and ~90% specificity for mRNA/miRNA by PCR), cytology performs well (sensitivity ~0.92, specificity ~0.94), while vital staining, tissue reflectance, autofluorescence and chemiluminescence show wide ranges of sensitivity and specificity and overall limited evidence to replace conventional exam and biopsy
    Definitions
    Oral cancerCancer occurring in the oral cavity between the vermilion border of the lips and the junction of the hard and soft palates or the posterior one third of the tongue.
    HPV E6/E7 mRNAmRNA expression testing for HPV E6/E7 oncogenes used to determine high-risk HPV tumor status.
    p16 IHCImmunohistochemistry for p16 expression used as a surrogate marker for HPV tumor status.

    Revision History

    Policy Summary
    Payerblue cross blue shield - tennessee
    PolicyOral Cancer Screening and Testing
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionProvider must document that the individual has oropharyngeal squamous cell carcinoma when requesting HPV tumor status testing (p16 IHC or HPV E6/E7 mRNA).
    SourceLink
    On This Page
    Coverage SummaryMedical-Necessity CriteriaCodingProvider ActionsBackground & EvidenceRevision History
    • 87624
    • 87625
    • 0429U
    • 88342
    • 88341
    • 81599
    • 82397
    Denial Risk

    Claims for excluded tests may be denied

    Claims for salivary biomarker testing, HPV genotyping via salivary OraRisk® HPV, gene expression profiling, and combined genetic/non-genetic panels do not meet coverage criteria and are subject to denial.

    Salivary biomarker testingTests analyzing saliva for peptides/proteins, nucleic acids, or metabolites to screen/detect oral cancer.